Brain amyloid in preclinical Alzheimer's disease is associated with increased driving risk

Brian R. Ott, Richard N. Jones, Richard B. Noto, Don C. Yoo, Peter J. Snyder, Justine N. Bernier, David B. Carr, Catherine M. Roe

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Introduction Postmortem studies suggest that fibrillar brain amyloid places people at higher risk for hazardous driving in the preclinical stage of Alzheimer's disease (AD). Methods We administered driving questionnaires to 104 older drivers (19 AD, 24 mild cognitive impairment, and 61 cognitive normal) who had a recent 18F-florbetapir positron emission tomography scan. We examined associations of amyloid standardized uptake value ratios with driving behaviors: traffic violations or accidents in the past 3 years. Results The frequency of violations or accidents was curvilinear with respect to standardized uptake value ratios, peaking around a value of 1.1 (model r2 = 0.10, P = 002); moreover, this relationship was evident for the cognitively normal participants. Discussion We found that driving risk is strongly related to accumulating amyloid on positron emission tomography, and that this trend is evident in the preclinical stage of AD. Brain amyloid burden may in part explain the increased crash risk reported in older adults.

Original languageEnglish
Pages (from-to)136-142
Number of pages7
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
StatePublished - 2017


  • Alzheimer's disease
  • Assessment of cognitive disorders
  • Biomarkers
  • Cognitive aging
  • Dementia
  • Driving
  • MCI (mild cognitive impairment)


Dive into the research topics of 'Brain amyloid in preclinical Alzheimer's disease is associated with increased driving risk'. Together they form a unique fingerprint.

Cite this